Multiple sclerosis, natalizumab, immunoglobulin levels: a longitudinal analysis

被引：0
|
作者：
Kaczmarek, O. [1 ]
Sethi, A. [1 ]
Chee, J. [1 ]
Bumstead, B. [1 ]
Buhse, M. [1 ]
Zarif, M. [1 ]
Scott, N. [2 ]
Gocke, A. [2 ]
Gudesblatt, M. [1 ]
机构：
[1] South Shore Neurol Associates PC, Patchogue, NY USA
[2] Biogen Inc, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P363
引用
收藏
页码：360 / 360
页数：1
相关论文
共 50 条
  • [21] Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis
    Gaughan, M.
    Gilligan, M.
    Patterson, I.
    McGurgan, I.
    Yap, S. M.
    Tubridy, N.
    McGuigan, C.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [22] Natalizumab therapy in multiple sclerosis
    Stueve, O.
    [J]. MULTIPLE SCLEROSIS, 2007, 13 (09): : 1210 - 1210
  • [23] Natalizumab Therapy for Multiple Sclerosis
    Derfuss, Tobias
    Kuhle, Jens
    Lindberg, Raija
    Kappos, Ludwig
    [J]. SEMINARS IN NEUROLOGY, 2013, 33 (01) : 26 - 36
  • [24] Natalizumab in Pediatric Multiple Sclerosis
    Talab, R.
    Talabova, M.
    Klzo, L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 931 - 931
  • [25] Monitoring of natalizumab serum levels in a portuguese multiple sclerosis outpatient clinic
    Correia Sa, Joao Carlos
    Ferreira, Joao
    Santos, Monica
    Figueiredo, Sonia
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 980 - 981
  • [26] Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis
    Gaughan, M.
    Gilligan, M.
    Patterson, I
    McGurgan, I
    Yap, S. M.
    Tubridy, N.
    McGuigan, C.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
  • [27] Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study
    Stephenson, Judith J.
    Kern, David M.
    Agarwal, Sonalee S.
    Zeidman, Ruth
    Rajagopalan, Krithika
    Kamat, Siddhesh A.
    Foley, John
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2012, 10
  • [28] SERUM IMMUNOGLOBULIN LEVELS IN MULTIPLE-SCLEROSIS IN ORKNEY
    ALAGIDI, SK
    ROBERTS, DF
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 1979, 60 (05): : 320 - 327
  • [29] Exposure–disease response analysis of natalizumab in subjects with multiple sclerosis
    Kumar Kandadi Muralidharan
    Deb Steiner
    Diogo Amarante
    Pei-Ran Ho
    Dan Mikol
    Jacob Elkins
    Meena Subramanyam
    Ivan Nestorov
    [J]. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44 : 263 - 275
  • [30] q-Space Myelin Map imaging for longitudinal analysis of remyelination in multiple sclerosis patients treated with natalizumab
    Kufukihara, K.
    Tanikawa, M.
    Hata, J.
    Suzuki, S.
    Fujiyoshi, K.
    Fujiwara, H.
    Jinzaki, M.
    Nakamura, M.
    Okano, H.
    Takahashi, S.
    Nakahara, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 434 - 435
12345